Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

THE USE OF FRESH HUMAN SERUM (COMPLEMENT) IN MENINGOCOCCUS MENINGITIS

THE USE OF FRESH HUMAN SERUM (COMPLEMENT) IN MENINGOCOCCUS MENINGITIS In 1908 the successful treatment of ten out of sixteen cases of acute meningococcus meningitis by means of fresh human serum (without the addition of antiserum) given intraspinally was reported by McKenzie and Martin.1 They used normal, convalescent and patients' serums and extended their study by showing that each serum, in vitro, exerted a meningococcidal power by means of a thermolabile constituent. In 1916, Fairley and Stewart2 added fresh human (convalescent) serum to antimeningococcus serum before intraspinal administration and reported seven recoveries out of ten acute cases thus treated. Two years later, Kolmer and his associates3 showed by well controlled experiments that the addition of normal active human or guinea-pig serum to antimeningococcus serum definitely increased its opsonic and to a lesser extent its bactericidal activity. Dr. Kolmer4 has informed us of five unreported cases of the successful clinical application of this principle. However, the literature http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

THE USE OF FRESH HUMAN SERUM (COMPLEMENT) IN MENINGOCOCCUS MENINGITIS

BUNIM, JOSEPH J.; WIES, FREDERICK A.
JAMA , Volume 100 (3) – Jan 21, 1933
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/the-use-of-fresh-human-serum-complement-in-meningococcus-meningitis-A5rk0unCJq

References (3)

Publisher
American Medical Association
Copyright
Copyright © 1933 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1933.02740030026009
Publisher site
See Article on Publisher Site

Abstract

In 1908 the successful treatment of ten out of sixteen cases of acute meningococcus meningitis by means of fresh human serum (without the addition of antiserum) given intraspinally was reported by McKenzie and Martin.1 They used normal, convalescent and patients' serums and extended their study by showing that each serum, in vitro, exerted a meningococcidal power by means of a thermolabile constituent. In 1916, Fairley and Stewart2 added fresh human (convalescent) serum to antimeningococcus serum before intraspinal administration and reported seven recoveries out of ten acute cases thus treated. Two years later, Kolmer and his associates3 showed by well controlled experiments that the addition of normal active human or guinea-pig serum to antimeningococcus serum definitely increased its opsonic and to a lesser extent its bactericidal activity. Dr. Kolmer4 has informed us of five unreported cases of the successful clinical application of this principle. However, the literature

Journal

JAMA – American Medical Association

Published: Jan 21, 1933

There are no references for this article.